An additional consequence of greater injection frequency is the potential for earlier progression of macular atrophy (also termed geographic atrophy in the literature), which has been hypothesised as being exacerbated over time with intensive, long-term anti-VEGF therapy. The gene discussed is VEGFA; the disease is atrophic macular degeneration.